Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Filleron

Showing results (71-80 of 199) with videos related to

Pageof 20
Sort By:
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Expert Review of Molecular Diagnostics|October 28, 2015
What to expect from molecular tools for non-documented pediatric infectious diseasesAnne Filleron, Anne-Laure Michon, Estelle Jumas-Bilak, et al.
BMC Urology|June 9, 2016
Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancerJean-Baptiste Beauval, Mathieu Roumiguié, Thomas Filleron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Perception of lung cancer among the general population and comparison with other cancersJulien Mazières, Jean-Louis Pujol, Nikos Kalampalikis, et al.
Cancer Medicine|June 7, 2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in FranceDidier Debieuvre, Pauline Macouillard, Xavier Quantin, et al.
Plastic and Reconstructive Surgery|November 24, 2015
A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free FlapsSamuel Riot, Christian Herlin, Ali Mojallal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Addressing heterogeneity in the design of phase II clinical trials in geriatric oncologyBastien Cabarrou, Patrick Sfumato, Loïc Mourey, et al.
Brachytherapy|March 12, 2018
New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverageThomas Brun, Jean-Marc Bachaud, Pierre Graff-Cailleaud, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 7, 2023
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamideThibaud Valentin, Marie Lambert, Léonor Chaltiel, et al.
European Urology|February 27, 2023
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor TrialsAna Cavillon, Damien Pouessel, Nadine Houédé, et al.
Pageof 20

Showing results (71-80 of 199) with videos related to

Sort By:
Pageof 20
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Expert Review of Molecular Diagnostics|October 28, 2015
What to expect from molecular tools for non-documented pediatric infectious diseasesAnne Filleron, Anne-Laure Michon, Estelle Jumas-Bilak, et al.
BMC Urology|June 9, 2016
Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancerJean-Baptiste Beauval, Mathieu Roumiguié, Thomas Filleron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Perception of lung cancer among the general population and comparison with other cancersJulien Mazières, Jean-Louis Pujol, Nikos Kalampalikis, et al.
Cancer Medicine|June 7, 2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in FranceDidier Debieuvre, Pauline Macouillard, Xavier Quantin, et al.
Plastic and Reconstructive Surgery|November 24, 2015
A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free FlapsSamuel Riot, Christian Herlin, Ali Mojallal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2018
Addressing heterogeneity in the design of phase II clinical trials in geriatric oncologyBastien Cabarrou, Patrick Sfumato, Loïc Mourey, et al.
Brachytherapy|March 12, 2018
New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverageThomas Brun, Jean-Marc Bachaud, Pierre Graff-Cailleaud, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 7, 2023
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamideThibaud Valentin, Marie Lambert, Léonor Chaltiel, et al.
European Urology|February 27, 2023
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor TrialsAna Cavillon, Damien Pouessel, Nadine Houédé, et al.
Pageof 20